ESSA Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company, announced on Tuesday that it has named Philip Kantoff, MD, as its new director.

Presently, Dr Kantoff serves as the chief executive officer and co-founder of Convergent Therapeutics. He has held the position of chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK), and is Professor of Medicine at Harvard Medical School and the Jerome and Nancy Kohlberg Chair at Harvard Medical School.

Richard M Glickman, LLD. (Hon), Chairman of ESSA's Board of Directors, said, 'Phil's breadth and quality of accomplishments are unmatched, and we are honoured to welcome him to ESSA's Board of Directors. We are eager to leverage Phil's admirable expertise in prostate cancer clinical research, as we work to further ESSA's pipeline of first-in-class anitens targeting the N-terminal domain of the androgen receptor.'